Dobutamine	dobutamine	S_chemical	O
stress	stress	O	O
echocardiography	echocardiography	O	O
:	:	O	O
a	a	O	O
sensitive	sensitive	O	O
indicator	indicator	O	O
of	of	O	O
diminished	diminished	O	O
myocardial	myocardial	O	O
function	function	O	O
in	in	O	O
asymptomatic	asymptomatic	O	O
doxorubicin-treated	doxorubicin-treated	O	O
long-term	long-term	O	O
survivors	survivors	O	O
of	of	O	O
childhood	childhood	O	O
cancer	cancer	O	S_disease
.	.	O	O

Doxorubicin	doxorubicin	S_chemical	O
is	is	O	O
an	an	O	O
effective	effective	O	O
anticancer	anticancer	O	O
chemotherapeutic	chemotherapeutic	O	O
agent	agent	O	O
known	known	O	O
to	to	O	O
cause	cause	O	O
acute	acute	O	O
and	and	O	O
chronic	chronic	O	O
cardiomyopathy	cardiomyopathy	O	S_disease
.	.	O	O

To	to	O	O
develop	develop	O	O
a	a	O	O
more	more	O	O
sensitive	sensitive	O	O
echocardiographic	echocardiographic	O	O
screening	screening	O	O
test	test	O	O
for	for	O	O
cardiac	cardiac	O	O
damage	damage	O	O
due	due	O	O
to	to	O	O
doxorubicin	doxorubicin	S_chemical	O
,	,	O	O
a	a	O	O
cohort	cohort	O	O
study	study	O	O
was	was	O	O
performed	performed	O	O
using	using	O	O
dobutamine	dobutamine	S_chemical	O
infusion	infusion	O	O
to	to	O	O
differentiate	differentiate	O	O
asymptomatic	asymptomatic	O	O
long-term	long-term	O	O
survivors	survivors	O	O
of	of	O	O
childhood	childhood	O	O
cancer	cancer	O	S_disease
treated	treated	O	O
with	with	O	O
doxorubicin	doxorubicin	S_chemical	O
from	from	O	O
healthy	healthy	O	O
control	control	O	O
subjects	subjects	O	O
.	.	O	O

Echocardiographic	echocardiographic	O	O
data	data	O	O
from	from	O	O
the	the	O	O
experimental	experimental	O	O
group	group	O	O
of	of	O	O
21	21	O	O
patients	patients	O	O
(	(	O	O
mean	mean	O	O
age	age	O	O
16	16	O	O
+	+	O	O
/-	/-	O	O
5	5	O	O
years	years	O	O
)	)	O	O
treated	treated	O	O
from	from	O	O
1.6	1.6	O	O
to	to	O	O
14.3	14.3	O	O
years	years	O	O
(	(	O	O
median	median	O	O
5.3	5.3	O	O
)	)	O	O
before	before	O	O
this	this	O	O
study	study	O	O
with	with	O	O
27	27	O	O
to	to	O	O
532	532	O	O
mg/m2	mg/m2	O	O
of	of	O	O
doxorubicin	doxorubicin	S_chemical	O
(	(	O	O
mean	mean	O	O
196	196	O	O
)	)	O	O
were	were	O	O
compared	compared	O	O
with	with	O	O
echocardiographic	echocardiographic	O	O
data	data	O	O
from	from	O	O
12	12	O	O
normal	normal	O	O
age-matched	age-matched	O	O
control	control	O	O
subjects	subjects	O	O
.	.	O	O

Graded	graded	O	O
dobutamine	dobutamine	S_chemical	O
infusions	infusions	O	O
of	of	O	O
0.5	0.5	O	O
,	,	O	O
2.5	2.5	O	O
,	,	O	O
5	5	O	O
and	and	O	O
10	10	O	O
micrograms/kg	micrograms/kg	O	O
per	per	O	O
min	min	O	O
were	were	O	O
administered	administered	O	O
.	.	O	O

Echocardiographic	echocardiographic	O	O
Doppler	doppler	O	O
studies	studies	O	O
were	were	O	O
performed	performed	O	O
before	before	O	O
infusion	infusion	O	O
and	and	O	O
after	after	O	O
15	15	O	O
min	min	O	O
of	of	O	O
infusion	infusion	O	O
at	at	O	O
each	each	O	O
rate	rate	O	O
.	.	O	O

Dobutamine	dobutamine	S_chemical	O
infusion	infusion	O	O
at	at	O	O
10	10	O	O
micrograms/kg	micrograms/kg	O	O
per	per	O	O
min	min	O	O
was	was	O	O
discontinued	discontinued	O	O
after	after	O	O
six	six	O	O
studies	studies	O	O
secondary	secondary	O	O
to	to	O	O
a	a	O	O
50	50	O	O
%	%	O	O
incidence	incidence	O	O
rate	rate	O	O
of	of	O	O
adverse	adverse	O	O
symptoms	symptoms	O	O
.	.	O	O

The	the	O	O
most	most	O	O
important	important	O	O
findings	findings	O	O
were	were	O	O
that	that	O	O
compared	compared	O	O
with	with	O	O
values	values	O	O
in	in	O	O
control	control	O	O
subjects	subjects	O	O
,	,	O	O
end-systolic	end-systolic	O	O
left	left	O	O
ventricular	ventricular	O	O
posterior	posterior	O	O
wall	wall	O	O
dimension	dimension	O	O
and	and	O	O
percent	percent	O	O
of	of	O	O
left	left	O	O
ventricular	ventricular	O	O
posterior	posterior	O	O
wall	wall	O	O
thickening	thickening	O	O
in	in	O	O
doxorubicin-treated	doxorubicin-treated	O	O
patients	patients	O	O
were	were	O	O
decreased	decreased	O	O
at	at	O	O
baseline	baseline	O	O
study	study	O	O
and	and	O	O
these	these	O	O
findings	findings	O	O
were	were	O	O
more	more	O	O
clearly	clearly	O	O
delineated	delineated	O	O
with	with	O	O
dobutamine	dobutamine	S_chemical	O
stimulation	stimulation	O	O
.	.	O	O

End-systolic	end-systolic	O	O
left	left	O	O
ventricular	ventricular	O	O
posterior	posterior	O	O
wall	wall	O	O
dimension	dimension	O	O
at	at	O	O
baseline	baseline	O	O
for	for	O	O
the	the	O	O
doxorubicin-treated	doxorubicin-treated	O	O
group	group	O	O
was	was	O	O
11	11	O	O
+	+	O	O
/-	/-	O	O
1.9	1.9	O	O
mm	mm	O	O
versus	versus	O	O
13.1	13.1	O	O
+	+	O	O
/-	/-	O	O
1.5	1.5	O	O
mm	mm	O	O
for	for	O	O
control	control	O	O
subjects	subjects	O	O
(	(	O	O
p	p	O	O
less	less	O	O
than	than	O	O
0.01	0.01	O	O
)	)	O	O
.	.	O	O

End-systolic	end-systolic	O	O
left	left	O	O
ventricular	ventricular	O	O
posterior	posterior	O	O
wall	wall	O	O
dimension	dimension	O	O
at	at	O	O
the	the	O	O
5-micrograms/kg	5-micrograms/kg	O	O
per	per	O	O
min	min	O	O
dobutamine	dobutamine	S_chemical	O
infusion	infusion	O	O
for	for	O	O
the	the	O	O
doxorubicin-treated	doxorubicin-treated	O	O
group	group	O	O
was	was	O	O
14.1	14.1	O	O
+	+	O	O
/-	/-	O	O
2.4	2.4	O	O
mm	mm	O	O
versus	versus	O	O
19.3	19.3	O	O
+	+	O	O
/-	/-	O	O
2.6	2.6	O	O
mm	mm	O	O
for	for	O	O
control	control	O	O
subjects	subjects	O	O
(	(	O	O
p	p	O	O
less	less	O	O
than	than	O	O
0.01).(ABSTRACT	0.01).(abstract	O	O
TRUNCATED	truncated	O	O
AT	at	O	O
250	250	O	O
WORDS	words	O	O
)	)	O	O

